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Abstract
Background: Primary percutaneous coronary intervention (pPCI) in ST-segment elevation myocar-
dial infarction (STEMI) can be challenging for high thrombus burden and catecholamine-induced 
vasoconstriction. The Xposition-S stent was designed to prevent stent undersizing and minimize strut 
malapposition. We evaluated 1-year clinical outcomes of a nitinol, self-apposing®, sirolimus-eluting 
stent, pre-mounted on a novel balloon delivery system, in de novo lesions of patients presenting with 
STEMI undergoing pPCI.
Methods: The iPOSITION is a prospective, multicenter, post-market, observational study. The primary 
endpoint, target lesion failure (TLF), was defined as the composite of cardiac death, recurrent target vessel 
myocardial infarction (TV-MI), and clinically driven target lesion revascularization (TLR). 
Results: The study enrolled 247 STEMI patients from 7 Italian centers. Both device and procedural 
success occurred in 99.2% of patients, without any death, TV-MI, TLR, or stent thrombosis during the 
hospital stay and at 30-day follow-up. At 1 year, TLF occurred in 2.6%, cardiac death occurred in 1.7%, 
TV-MI occurred in 0.4%, and TLR in 0.4% of patients. The 1-year stent thrombosis rate was 0.4%. 
Conclusions: The use of an X-position S self-apposing® stent is feasible in STEMI pPCI, with excellent 
post-procedural results and 1-year outcomes. (Cardiol J 20XX; XX, X: xx–xx)
Key words: acute myocardial infarction, ST-segment elevation myocardial infarction, 
clinical trials, self-apposing stent, nitinol stent, interventional device/innovation,  
percutaneous coronary intervention (PCI), complex, primary PCI, drug-eluting stent
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Introduction
Ischemic heart disease is the leading cause 
of death worldwide. The incidence of ST-segment 
elevation myocardial infarction (STEMI) ranges 
from 43 to 144 new cases per 100,000 per year in 
Europe, with 116 per 100,000 cases per year in 
Italy [1]. In STEMI, prompt reperfusion by primary 
percutaneous coronary intervention (pPCI) and 
drug-eluting stent (DES) implantation is the rec-
ommended strategy, within indicated timeframes 
[2, 3]. In the acute phase, catecholamine-induced 
vasoconstriction and high thrombus burden can 
interfere with proper lumen diameter evaluation 
and stent sizing. Subsequently, the dissolution of 
jailed thrombotic material and vessel relaxation can 
result in strut malapposition, with increased risk of 
stent thrombosis over time [4–6]. A self-apposing® 
stent, which dynamically adapts to the vessel 
wall after the index procedure with a continuous 
radial force, can be a promising therapeutic option 
[7–9]. This observational study aimed to collect 
clinical data to evaluate the safety and efficacy of 
a nitinol, self-apposing®, sirolimus-eluting stent, 
pre-mounted on a novel balloon delivery system, 
in de novo lesions of native coronary arteries of 
patients presenting with STEMI. 
Methods
Study overview
The iPOSITION Registry (Prospective, ob-
servational, Italian multi-center registry of self-
aPposing® cOronary Stent in patients presenting 
with ST-segment Elevation Myocardial Infarc-
TION) was an Italian, prospective, multicenter, 
post-market, observational study. The study was 
conducted in full conformity with the Declaration 
of Helsinki and approved by the local medical eth-
ics committees of all participating sites. Written 
informed consent was obtained before inclusion. 
The iPOSITION study was registered to the Na-
tional Institutes of Health database with reference 
number NCT02979236 (full details available at 
https://clinicaltrials.gov).
Patient selection and procedural instructions
Patients older than 18 years, presenting with 
STEMI, undergoing pPCI, in which use of the 
Xposition S (STENTYS S.A., Paris, France) stent 
was planned at the operator’s discretion, were 
eligible for inclusion. Patients with at least one of 
the following criteria were excluded: cardiogenic 
shock at presentation, severe tortuous vessels, 
highly calcified lesions, intrastent pathology, mul-
tiple lesions requiring stenting in the target vessel, 
known allergies to stent components, inability to 
comply with dual antiplatelet therapy (DAPT), 
known comorbidities conditioning life expectancy 
to less than 1 year, known pregnancy or child-
bearing potential, and inability to provide written 
informed consent. Accurate lesion preparation with 
pre-dilation was encouraged, when deemed feasi-
ble, to obtain a residual stenosis diameter < 30%. 
Post-dilation was recommended, preferably using 
a non-compliant balloon of the same size of the ref-
erence vessel diameter. After the pPCI procedure, 
all patients were transferred to a coronary intensive 
care unit and treated according to local protocols.
Device description
The Xposition S, available on the market 
since the beginning of 2016, is a new generation 
self-apposing® DES, pre-mounted on a novel bal-
loon delivery system (Fig. 1). The stent is made of 
a Z-shaped mesh of nitinol (nickel/titanium alloy) and 
incorporates 1.4 μg/mm2 of sirolimus in a durable 
polymer matrix (ProTeqtor®) of polysulfone and 
soluble polyvinylpyrrolidone. Small interconnec-
tions between stent struts allow disconnections 
for easy side branch access in bifurcation setting. 
The stent is available in four lengths (17, 22, 27, 
and 37 mm) and three sizes suitable for reference 
vessel diameters of 2.5–3.0 mm (small), 3.0–3.5 
mm (medium), and 3.5–4.5 mm (large), compatible 
with a maximum vessel diameter of 6 mm (Fig. 1E). 
Strut thickness ranges from 103 μm (small size) 
to 133 μm (medium and large sizes). The stent is 
folded on a delivery balloon, which is covered with 
a distal “splitable” sheath assembly. The nominal 
diameter of the delivery balloon is the same as the 
smallest diameter for which the stent is suitable. 
When the semi-compliant delivery balloon is in-
flated within the sheath with a pressure of at least 
12 atmospheres, the sheath assembly splits, and 
the stent is deployed. The sheath is then withdrawn 
together with the balloon. 
Endpoints
The primary endpoint was the occurrence 
of target lesion failure (TLF) at 1-year follow-up. 
TLF was defined as the composite of cardiac death 
(CD), recurrent target vessel myocardial infarction 
(TV-MI), and clinically driven target lesion revas-
cularization (TLR). Secondary endpoints included 
the following: 30-day TLF, procedural success 
during the hospital stay, death from any cause, 
30-day and 1-year stent thrombosis (ST), and any 
Figure 1. The Xposition S drug-eluting stent; A. The stent is pre-mounted on a semi-compliant balloon and is re-
strained by a pre-cut sheath; B. Balloon inflation splits the stent from distal to proximal and releases the self-apposing® 
stent; C. The balloon is then deflated; D. The balloon and the sheath are then withdrawn leaving the stent apposed 
to the vessel wall; E. Xposition S stent sizes.
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individual component of the primary endpoint. 
Procedural success was defined as any device suc-
cess with the obtainment of vessel recanalization 
(Thrombolysis in Myocardial Infarction [TIMI] 
grade 2–3 flow), a diameter stenosis ≤ 30% and 
without the occurrence of death, reinfarction, or 
repeated revascularization of the target vessel dur-
ing the hospital stay. DAPT compliance was also 
investigated. A detailed overview of endpoint defi-
nition is provided in Supplementary Appendix 1.
Sample size calculation
The predicted rate of 1-year TLF primary 
endpoint was 2.5% on the basis of data reported 
by a previous registry [10]. Hence, a minimum 
sample size of 235 patients was considered enough 
to provide a ± 2% estimation of the primary out-
come with a type-I error of 5% and a power of 
80%. Taking into account 5% as a possible rate 
of loss at follow-up, a total of 247 patients were 
finally enrolled.
Statistical methods
Continuous variables were presented as mean 
± standard deviation in the case of a normal distri-
bution; conversely; when they were non-normally 
distributed, medians and quartiles were reported. 
Categorical variables were presented as frequen-
cies and percentages. Time-to-event analysis was 
performed using Kaplan-Meier survival curves; 
the comparison between curves was obtained 
with the log-rank test. We considered p < 0.05 
for statistical significance. Variables associated 
with 1-year TLF were identified by univariate Cox 
proportional hazard regression. Hazard ratios (HR), 
95% confidence intervals (95% CI), and p-values 
were reported. All the analyses were performed 
with SPSS (IBM Corp., IBM SPSS Version 24.0., 
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Armonk, NY, US), Med-Calc (MedCalc Software bv, 
Ostend, Belgium), and R-project (Core Team 2013, 
R Foundation for Statistical Computing, Vienna, 
Austria); p < 0.05 was considered as the threshold 
for statistical significance. 
Results
A total of 247 STEMI patients were enrolled 
in 7 Italian centers from June 2016 to July 2018. 
Eighteen patients were lost at 1-year follow-up, so 
the final analysis was performed on 229 patients. 
Baseline characteristics
Demographic characteristics are presented in 
Table 1. The mean age was 61 ± 11 years, with the 
majority being male (83%). More than half of the 
patients had systemic arterial hypertension (51%), 
and almost one in two was an active cigarette smoker 
(46%), 30% had coronary artery disease, a quarter 
had hypercholesterolemia (25%), and 13% had dia-
betes mellitus. Most of the patients presented in 
Killip class I (88.7%), with more than a half less than 
3 h from symptom onset (54%). Culprit lesions were 
identified predominantly in the right coronary artery 
(43%) and the left anterior descending coronary 
artery (41%). Only a minority of patients required 
a pPCI of the left main (n = 4). High thrombus 
burden (TIMI thrombus burden 4–5) was identified 
in 41% of lesions and required thrombus aspiration 
in 30% of cases; 24% of lesions involved a bifurca-
tion site. A complete overview of angiographic and 
procedural characteristics is summarized in Table 1. 
Primary endpoint
Eighteen (7.3%) patients were lost at 1-year 
follow-up. The primary endpoint of 1-year TLF 
occurred in 6 patients (2.6%; 95% CI 0.53–4.67). 
Four patients died, and all events were attributed 
to a cardiac cause, resulting in a 1-year cardiac 
death rate of 1.7% (95% CI 0.03–3.37). Recurrent 
TV-MI was observed in 1 patient (0.4%; 95% CI 
0.0–1.22). Clinically indicated TLR was performed 
in 1 patient (0.4%; 95% CI 0.0–1.22). Freedom 
from TLF at 1-year follow-up was 97.4% ± 1.1%; it 
was significantly higher in patients whose lesions 
were treated with pre-dilation (98.4% ± 0.9% vs. 
92.5% ± 4.2%, p = 0.03; Fig. 2A) and lower with 
thrombus aspiration (94.1% ± 2.9% vs. 98.7% ± 
± 0.9%, p = 0.04; Fig. 2B). At univariate Cox re-
gression, performing pre-dilation was associated 
with better freedom from TLF (HR = 0.21, 95% 
CI 0.04–0.97); conversely, thrombus aspiration 
was associated with worse freedom from TLF 
Table 1. iPOSITION baseline demographic  
characteristics, clinical history, cardiovascular 
risk factors, clinical presentation, and procedural 
characteristics. 
BASELINE CHARACTERISTICS
Age [years] 60.9 ± 10.9
Sex (male) 204 (82.6%)
Clinical history
Previous MI (> 30 days) 9 (3.6%)
Previous CABG 3 (1.2%)
Previous PCI 11 (4.5%)
Previous stroke/TIA 4 (1.6%)
Cardiovascular risk factors
Hypertension 126 (51.0%)
Diabetes mellitus 33 (13.4%)




Active smoker 113 (45.7%)
Former smoker 33 (13.4%)
Family history CAD 74 (30%)
Hypercholesterolemia 62 (25.1%)
Time from onset of symptoms
< 3 h 134 (54.3%)
≥ 3 h and < 6 h 74 (30.0%)
≥ 6 h and <12 h 28 (11.3%)














Reference vessel diameter [mm] 3.40 ± 0.46
Length [mm] 26.1 ± 10.5
High thrombus burden  
(TIMI thrombus grade ≥ 4)
101 (40.9%)
Ostial lesion 18 (7.3%)
Bifurcation 58 (23.5%)
Calcifications (≥ mild) 37 (15.0%)
Tortuosity (≥ mild) 12 (4.9%)
Xposition S size
S (2.5–3.0 mm) 60 (24.3%)
Æ
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(HR = 4.9, 95% CI 1.1–26.5). All the other variables 
reported in Table 1 were also tested, but none of 
them was significantly associated with 1-year TLF.
Secondary endpoint
Both device and procedural success occurred 
in 99.2% (95% CI 98.09–100%) of patients, without 
any death, recurrent TV-MI, TLR, or ST during 
the hospital stay and at 30-day follow-up. A single 
event of possible ST occurred, resulting in a 1-year 
ST rate of 0.4% (95% CI 0.0–1.22%).
DAPT compliance
Almost all patients were on DAPT after dis-
charge (99%), 94% with a potent P2Y12 inhibitor (tica-
grelor or prasugrel) and acetylsalicylate (n = 232). 
A total of 95% of patients (n = 213) were still on 
DAPT at 1-year follow-up. Three patients had 
switched to oral anticoagulation for atrial fibrilla-
tion or mechanical heart valve implantation. The 
remaining 4% of patients (n = 9) had switched to 
a single antiplatelet therapy, four with acetylsali-
cylate and five with a P2Y12 inhibitor.
Discussion
Main findings
The present post-marketing registry clearly 
shows that the use of the Xposition S self-appos-
ing® stent is feasible in pPCI, with an excellent 
result in almost all STEMI patients. Good mid-
term outcomes corroborate such findings, with 
a significant TLF risk reduction when lesions 
were prepared with pre-dilation, without thrombus 
Table 1 (cont.). iPOSITION baseline demographic 
characteristics, clinical history, cardiovascular 
risk factors, clinical presentation, and procedural 
characteristics. 
M (3.0–3.5 mm) 127 (51.4%)
L (3.5–4.5 mm) 60 (24.3%)
Xposition S length
17 mm 30 (12.1%)
22 mm 86 (34.8%)
27 mm 73 (29.6%)
37 mm 58 (23.5%)
Techniques used
QCA assessment 12 (4.9%)
Intravascular imaging (IVUS or OCT) 6 (2.4%)










Postprocedural vessel dissection 3 (1.2%)
Variables have been reported as mean ± standard deviation or 
number (%). MI — myocardial infarction; CABG — coronary artery 
by-pass graft; PCI — percutaneous coronary intervention; TIA — 
transient ischemic attack; GFR — glomerular filtration rate; CAD —  
coronary artery disease; RCA — right coronary artery; LM — left 
main; LAD — left anterior descending coronary artery; LCX — left 
circumflex coronary artery; TIMI —Thrombolysis in Myocardial 
Infarction; QCA — quantitative coronary analysis; IVUS — intravas-
cular ultrasound; OCT — optical coherence tomography
Figure 2. A. Freedom from target lesion failure at 1 year; comparison between patients whose lesions were treated 
with pre-dilation (solid line) and those whose were not (dashed line); B. Freedom from target lesion failure at 1 year; 
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aspiration. Procedural and clinical outcomes were 
comparable to other currently available balloon-
-expandable DES in the same setting [11–13]. The 
APPOSITION III study [9, 10] investigated clinical 
outcomes in STEMI pPCI with the previous version 
of the same device. Although a direct comparison 
cannot be performed, we here document a much 
lower ST, leading to a lower 1-year TLF rate, be-
cause only a single possible ST event was observed. 
Several factor potentially contributed to this notable 
outcome improvement. First, the introduction and 
the extensive use of the more potent P2Y12 inhibi-
tors could have strongly  reduced thrombotic events 
[14]. Secondly, as we learned from the APPOSITION 
III itself [9, 10], a higher post-dilation rate might 
have reduced events by the improvement of strut 
apposition. Thirdly, even when post-dilation was 
not performed, the new releasing system in the 
iPOSITION may have guaranteed a larger stent 
expansion because of the balloon inflation, whereas 
in the APPOSITION III the stent expansion was left 
solely to its elastic properties, with an increasing 
risk of stent under-expansion [15–18]. 
We observed a high rate of 1-year DAPT com-
pliance in our study, and patients with inability to 
comply with DAPT were excluded as per the pro-
tocol. Therefore, our results cannot be extended 
to a high bleeding risk population [19]. 
Unfortunately, we have to acknowledge that 
the Xposition S self-apposing® stent is currently 
no longer available in the market. The Stentys 
Company claimed that its search for a strategic 
partner failed, and subsequently its shareholders 
voted for dissolution. 
Technical insight
Statistic regression with univariate Cox model 
and subgroup analysis (Fig. 2) revealed lesion pre-
dilation and avoidance of thrombus aspiration were 
associated with a lower 1-year TLF rate. The lack 
of clinical benefits of thrombus aspiration in STEMI 
pPCI has already been proven in randomized 
clinical trials [20–22]. Pre-dilation may favor lesion 
preparation before stenting, but concerns about the 
risk of no-reflow phenomenon due to thrombotic 
debridement and microcirculatory impairment 
often discourage this approach in STEMI [23–26]. 
The clinical benefit of pre-dilation in our study 
could be a hypothesis-generating result for further 
future investigations.
Limitations of the study
The results should be interpreted with cau-
tion because of several limitations: 1) iPOSITION 
enrolled non-randomized and non-consecutive 
patients, so a selection bias cannot be excluded, 
2) variables associated with 1-year TLF events 
were not tested in a multivariate model for low 
event rates, 3) clinical follow-up was limited to 
1 year, and a longer observation would be advisable 
to explore the response to DAPT demodulation, 
4) no data on the completeness of revascularization 
were collected [27], 5) events were not adjudicated 
by an independent clinical event committee, and 
6) a slightly high rate of patients were lost at 
follow-up.
Conclusions 
To the best of our knowledge, this is the first 
multicenter Italian registry evaluating the perfor-
mance of the nitinol self-apposing DES in a STEMI 
population and the first worldwide study weighing 
up the self-apposing DES novel balloon delivery 
system. Both procedural success and 1-year clini-
cal outcomes were excellent. Although acknowl-
edging the current unavailability of the device on 
the market, we should further investigate such 
a promising device in order to better define the role 
of self-apposing® DES in STEMI pPCI. 
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